The initiatives could change the way vaccine and drug trials are conducted in the United States, according to Reuters interviews with more than 40 public health and pharmaceutical-industry officials.
"This mindset about diversity - of not just being an afterthought but a central part of successful trials - is beginning to sink in," Dr. Francis Collins, director of the U.S. National Institutes of Health (NIH), told Reuters.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,